{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T07:01:39Z","timestamp":1775804499081,"version":"3.50.1"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Prostate cancer (PCa) is the most common malignant neoplasm of the urogenital system, with definitive diagnosis currently relying exclusively on prostate biopsy. Although the transperineal approach is associated with a lower incidence of perioperative complications, postoperative subcutaneous hematoma in the perineal region may be overlooked due to its anatomically concealed presentation, leading to delayed clinical attention. This report presents a case of extensive subcutaneous hematoma involving the lower abdomen and perineum following transperineal prostate biopsy in a patient diagnosed with PCa. Prompt management with prostatic artery angiography and superselective prostatic artery embolization, supplemented by endocrine therapy, resulted in rapid resolution of the hematoma. At three-month follow-up, tumor biomarkers remained stable, and key biochemical parameters had returned to pre-biopsy baseline levels, indicating favorable disease control and recovery.<\/jats:p>","DOI":"10.3389\/fonc.2026.1776163","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T06:06:39Z","timestamp":1775801199000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Subcutaneous hematoma of the lower abdomen and perineum following transperineal prostate biopsy: a case report and literature review"],"prefix":"10.3389","volume":"16","author":[{"given":"Zhiyong","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Urology, Hunan Provincial People\u2019s Hospital, The First Affiliated Hospital of Hunan Normal University","place":["Changsha, Hunan, China"]},{"name":"Clinical Medical College, Hunan Normal University","place":["Changsha, Hunan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhe","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Urology, Hunan Provincial People\u2019s Hospital, The First Affiliated Hospital of Hunan Normal University","place":["Changsha, Hunan, China"]},{"name":"Clinical Medical College, Hunan Normal University","place":["Changsha, Hunan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanwei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, Hunan Provincial People\u2019s Hospital, The First Affiliated Hospital of Hunan Normal University","place":["Changsha, Hunan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Urology, Hunan Provincial People\u2019s Hospital, The First Affiliated Hospital of Hunan Normal University","place":["Changsha, Hunan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongjun","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Urology, Hunan Provincial People\u2019s Hospital, The First Affiliated Hospital of Hunan Normal University","place":["Changsha, Hunan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.70043","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"Han","year":"2024","journal-title":"J Natl Cancer Cent"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-023-00729-4","article-title":"Transperineal magnetic resonance imaging targeted biopsy versus transrectal route in the detection of prostate cancer: a systematic review and meta-analysis","volume":"27","author":"Wu","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.12.015","article-title":"Transperineal versus transrectal magnetic resonance imaging-targeted and systematic prostate biopsy to prevent infectious complications: the PREVENT randomized trial","volume":"86","author":"Hu","year":"2024","journal-title":"Eur Urol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"39451","DOI":"10.1038\/s41598-025-23101-z","article-title":"Accuracy and safety of in-office transperineal freehand cognitive fusion prostate biopsy under local anaesthesia without antibiotic prophylaxis","volume":"15","author":"Lenart","year":"2025","journal-title":"Sci Rep"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0052","article-title":"Prostate cancer, version 3.2026, NCCN clinical practice guidelines in oncology","volume":"23","author":"Spratt","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"B7","volume-title":"Prostate cancer guidelines[EB\/OL]","year":"2026"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2022.03.07","article-title":"National guidelines for diagnosis and treatment of prostate cancer 2022 in China (English version)","volume":"34","year":"2022","journal-title":"Chin J Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003788","article-title":"Complications following transrectal and transperineal prostate biopsy: results of the ProBE-PC randomized clinical trial","volume":"211","author":"Mian","year":"2024","journal-title":"J Urol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1038\/s41598-022-05909-1","article-title":"Imaging of clinically silent rectoprostatic hematoma in MRI guided in-bore prostate biopsy","volume":"12","author":"Garmer","year":"2022","journal-title":"Sci Rep"},{"key":"B11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/jmri.24770","article-title":"3T MR-guided in-bore transperineal prostate biopsy: a comparison of robotic and manual needle-guidance templates","volume":"42","author":"Tilak","year":"2015","journal-title":"J Magn Reson Imaging"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eucr.2025.103030","article-title":"Retzius space hematoma after prostate biopsy: a case report","volume":"60","author":"Patel","year":"2025","journal-title":"Urol Case Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.5301\/uro.5000161","article-title":"Rare complication after a transrectal ultrasound guided prostate biopsy: a giant retroperitoneal hematoma","volume":"83","author":"Chiancone","year":"2016","journal-title":"Urologia"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.2135","article-title":"Intraprostatic hematoma with active bleeding post-prostate biopsy","volume":"8","author":"Guo","year":"2014","journal-title":"Can Urol Assoc J"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/BF02924068","article-title":"Prevesical hematoma: a complication of prostatic biopsy","volume":"8","author":"Choyke","year":"1986","journal-title":"Urol Radiol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/0090-4295(92)90279-6","article-title":"Anterior rectal wall hematoma: complication of transrectal ultrasound-guided biopsy of prostate","volume":"39","author":"Seymour","year":"1992","journal-title":"Urology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2019.08.007","article-title":"Complications and adverse events of three magnetic resonance imaging-based target biopsy techniques in the diagnosis of prostate cancer among men with prior negative biopsies: results from the FUTURE trial, a multicentre randomised controlled trial","volume":"2","author":"Wegelin","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117585","article-title":"Physiological and tumor-associated angiogenesis: key factors and therapy targeting VEGF\/VEGFR pathway","volume":"180","author":"Lorenc","year":"2024","journal-title":"BioMed Pharmacother"},{"key":"B19","doi-asserted-by":"publisher","first-page":"476.e1","DOI":"10.1016\/j.jvir.2020.10.022","article-title":"Society of interventional radiology quality improvement standards for percutaneous transcatheter embolization","volume":"32","author":"Dariushnia","year":"2021","journal-title":"J Vasc Interv Radiol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41392-024-02064-z","article-title":"Patient-reported outcomes of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer patients (CHART): a randomized, phase 3 study","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct Target Ther"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1776163\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T06:06:39Z","timestamp":1775801199000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1776163\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":20,"alternative-id":["10.3389\/fonc.2026.1776163"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1776163","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"article-number":"1776163"}}